Barclays Maintains Overweight on Oscar Health, Raises Price Target to $49

Barclays analyst Andrew Mok has maintained an Overweight rating on Oscar Health (NYSE: OSCR) and raised the price target from $39 to $49. This adjustment reflects a positive outlook on the company's performance.